Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GALK1 | P51570 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642960 | 0.93 | PTGS2 (0.47) | PTGS2AKR1B1CASP1ALDH1A1HSD17B10 | |
| SCHEMBL5711493 | 0.84 | PTGS2 (0.52) | PTGS2AKR1B1MEN1APAF1NPC1 | |
| SCHEMBL15879481 | 0.80 | PTGS2 (0.48) | PTGS2AKR1B1MEN1APAF1NPC1 | |
| SCHEMBL27842438 | 0.80 | CA1 (0.54) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL29353151 | 0.80 | PTGS2 (0.48) | PTGS2AKR1B1MEN1APAF1NPC1 | |
| SCHEMBL2447766 | 0.80 | PTGS2 (0.64) | PTGS2RAB9AL3MBTL1ALDH1A1PTGS1 | |
| SCHEMBL140117 | 0.80 | PTGS2 (0.48) | PTGS2AKR1B1MEN1APAF1NPC1 | |
| SCHEMBL2445593 | 0.79 | PTGS2 (0.48) | PTGS2MEN1APAF1NPC1LMNA | |
| SCHEMBL14740337 | 0.78 | PTGS2 (0.47) | PTGS2AKR1B1MEN1APAF1NPC1 | |
| SCHEMBL310988 | 0.78 | PTGS2 (0.47) | PTGS2AKR1B1MEN1APAF1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046350-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-23 | — | — | US | disclosed |
| US-8053598-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| EP-1745014-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-1558572-B1 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-1558571-B1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7709528-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090012171-A1 | Novel Compounds, Their Preparation and Use | NOVO NORDISK A/S (CZ) | 2009-01-08 | — | — | US | disclosed |
| US-20060287393-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2006-12-21 | — | — | US | disclosed |
| US-7129268-B2 | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives | NOVO NORDISK A/S (DK) | 2006-10-31 | — | — | US | disclosed |
| US-20050080115-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-04-14 | — | — | US | disclosed |
| US-20050070583-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287393-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PTGS2 554/4885AKR1B1 906/4885MEN1 4820/4885 |
| US-20050070583-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PTGS2 554/4885AKR1B1 906/4885MEN1 4820/4885 |
| US-20090012171-A1 | Novel Compounds, Their Preparation and Use | PPARG, PPARD, PPARA | PTGS2 603/4885AKR1B1 663/4885MEN1 4793/4885 |
| US-20050080115-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PTGS2 554/4885AKR1B1 906/4885MEN1 4820/4885 |
| US-20120046350-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | PPARG, PPARD, PPARA | PTGS2 554/4885AKR1B1 906/4885MEN1 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.